Active Biotech AB (ACTI.ST) Key Developments | Reuters.com
Edition:
United States

Active Biotech AB (ACTI.ST)

ACTI.ST on Stockholm Stock Exchange

11.00SEK
5:42am EDT
Change (% chg)

0.70kr (+6.80%)
Prev Close
10.30kr
Open
10.30kr
Day's High
11.70kr
Day's Low
10.25kr
Volume
73,467
Avg. Vol
61,583
52-wk High
17.30kr
52-wk Low
7.50kr

Latest Key Developments (Source: Significant Developments)

Active Biotech AB says no dividend would be paid
Friday, 27 May 2016 02:33am EDT 

Active Biotech Ab : Annual general meeting of active biotech ab . In accordance with board of directors' proposal, it was resolved that no dividend would be paid .Board members and managing director were discharged from liability with respect to their management of company for 2015.  Full Article

Active Biotech plans to develop tasquinimod for treatment of multiple myeloma
Wednesday, 23 Mar 2016 03:40am EDT 

Active Biotech AB:Plans to develop tasquinimod for the treatment of multiple myeloma.Says patent application for the treatment of multiple myeloma with the company's compound tasquinimod will be public within short.Says with this application, treatment of multiple myeloma with tasquinimod is potentially protected until 2035.Preclinical program was performed and very good results were achieved in models for multiple myeloma.Says will actively seek a collaboration partner for the development of tasquinimod within this indication.During 2016 orphan drug status applications for tasquinimod treatment of multiple myeloma are planned to be submitted to authorities in the EU and USA.Multiple myeloma is an incurable form of blood cancer where the plasma cells in the bone marrow grow uncontrollably while other blood forming cells such as white and red blood cells and blood platelets are suppressed.Says total market for multiple myeloma drugs amounted to 7.8 billion usd in 2013 (globaldata 2015).  Full Article

Active Biotech says stops higher doses MS trials of Laquinimod
Monday, 4 Jan 2016 09:01am EST 

Active Biotech AB:Says Teva and Active Biotech announce discontinuation of higher doses of Laquinimod in two multiple sclerosis trials.Says ‍occurrence of cardiovascular events, none of which was fatal, in eight patients​.Says ‍both trials, concerto and arpeggio, are continuing lower-dose arms (0.6mg daily), and participants in trials will be provided with an update to confirm re-consent for participation​.  Full Article

Active Biotech to present final phase 3 study results for tasquinimod
Monday, 28 Sep 2015 03:00am EDT 

Active Biotech AB:Says final results from Active biotech's 10tasq10 phase 3 study of tasquinimod presented at the ECC conference.Says final results show that tasquinimod treatment resulted in a prolonged radiographic progression free survival (rPFS), 7.0 vs. 4.4 months (central assessment) similar to an earlier Phase 2 study.Says the positive effect on rPFS did not translate into an improved OS (HR 1.097, 95 pct CI: 0.938-1.282).Tasquinimod safety was in general manageable and similar to what was observed during the Phase 2 study.  Full Article

Active Biotech says patient enrollment in laquinimod trial completed
Thursday, 25 Jun 2015 08:01am EDT 

Active Biotech AB:Active Biotech: Teva and Active Biotech announce completion of patient enrollment in laquinimod phase III Concerto trial.Says Concerto study results are expected to be available toward mid-2017.  Full Article

Active Biotech AB plans redundancies of 47 employees, downsizes operations
Monday, 1 Jun 2015 04:01am EDT 

Active Biotech AB:Says focuses the operations on the laquinimod project and adjusts the organization.Made a notification of planned redundancies of 47 of employees, which means a down-sizing of operations.Operating costs are expected to decrease to about 50 million Swedish crowns per year, from 2016.Says planned organizational adjustment leads to substantially reduced operating costs.  Full Article

Active Biotech and Ipsen to stop development of Tasquinimod in prostate cancer
Thursday, 16 Apr 2015 01:00am EDT 

Active Biotech AB:Active Biotech and Ipsen SA announce their decision to discontinue the development of Tasquinimod in prostate cancer.Efficacy results together with preliminary safety data do not support positive benefit risk balance.Full results will be presented at an upcoming scientific conference.  Full Article

Active Biotech says SEK 225 million rights issue oversubscribed
Monday, 29 Dec 2014 09:30am EST 

Active Biotech AB:Active Biotech's rights issue of about 225 million Swedish crowns oversubscribed.  Full Article

Active Biotech and Teva expand laquinimod clinical development program
Tuesday, 4 Nov 2014 08:00am EST 

Active Biotech AB:Teva and Active Biotech announce expansion of Laquinimod clinical development program with new trial in primary progressive multiple sclerosis and first patient screened in Huntington's Disease trial.  Full Article

Active Biotech AB's partner Teva initiates laquinimod clinical trial in Huntington's disease
Thursday, 14 Aug 2014 02:36am EDT 

Active Biotech AB:Says its partner Teva Pharmaceutical Industries Ltd. will initiate phase II clinical trial to evaluate efficacy and safety of oral laquinimod for treatment of Huntington's disease.  Full Article

BRIEF-Active Biotech plans to develop tasquinimod for treatment of multiple myeloma

* Active biotech plans to develop tasquinimod for the treatment of multiple myeloma